Ember Therapeutics to divest OP-1 product family and related assets to Viscogliosi Brothers

New York City-based Ember Therapeutics, a biopharmaceutical company, has agreed to sell its OP-1 product family and related assets, to Viscogliosi Brothers LLC, a private equity firm focused on developing neuromusculoskeletal technologies. No financial terms were disclosed.

DealsNorth AmericaUSHealthcareBriefs